The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future

Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used most notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such as LSD showed initial therapeutic promise before prohibitive legislature in the mid-1960s effectively ended all major psychedelic research programs. Since the early 1990s, there has been a steady revival of human psychedelic research: last year saw reports on the first modern brain imaging study with LSD and three separate clinical trials of psilocybin for depressive symptoms. In this circumspective piece, RLC-H and GMG share their opinions on the promises and pitfalls of renewed psychedelic research, with a focus on the development of psilocybin as a treatment for depression.

[1]  R. Strassman,et al.  Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. , 1994, Archives of general psychiatry.

[2]  Ido Hartogsohn.  Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology , 2016, Journal of psychopharmacology.

[3]  J. González-Maeso,et al.  Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: Effect of antidepressant treatment , 2014, Neuropharmacology.

[4]  James Rucker,et al.  Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. , 2016, The lancet. Psychiatry.

[5]  J. Riba,et al.  Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study , 2016, Journal of clinical psychopharmacology.

[6]  Richard G. Wise,et al.  Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin , 2012, Proceedings of the National Academy of Sciences.

[7]  J. Poirier,et al.  Polymorphism of the 5-HT2A Receptor Gene: Association with Stress-Related Indices in Healthy Middle-Aged Adults , 2007, Frontiers in behavioral neuroscience.

[8]  A. Hofmann,et al.  [Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim]. , 1958, Experientia.

[9]  K. Heekeren,et al.  Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis , 2010, Journal of psychopharmacology.

[10]  A. K. Busch,et al.  L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug. , 1950, Diseases of the nervous system.

[11]  P. Delgado,et al.  Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. , 2006, The Journal of clinical psychiatry.

[12]  M. Cahir.  British Association for Psychopharmacology Summer Meeting , 2006, Expert opinion on pharmacotherapy.

[13]  H. Mayberg,et al.  Stuck in a rut: rethinking depression and its treatment , 2011, Trends in Neurosciences.

[14]  S. Grof.  The Use of LSD in Psychotherapy , 1970 .

[15]  Jay Stevens,et al.  Storming Heaven: LSD and the American Dream , 1987 .

[16]  S. Krippner.  Moksha: Writings on Psychedelics and the Visionary Experience , 1982 .

[17]  J. Bakalar,et al.  Psychedelic Drugs Reconsidered , 1979 .

[18]  G. Lewith.  The treatment of tobacco addiction , 1995 .

[19]  H. Sackeim,et al.  The definition and meaning of treatment-resistant depression. , 2001, The Journal of clinical psychiatry.

[20]  D. Murphy,et al.  Chronic Administration of Serotonergic Antidepressants Attenuates the Subjective Effects of LSD in Humans , 1996, Neuropsychopharmacology.

[21]  Sidarta Ribeiro,et al.  The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network , 2015, PloS one.

[22]  Andreas Bäbler,et al.  Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.

[23]  H. Kobel,et al.  Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana Heim , 1958, Experientia.

[24]  S. Montgomery,et al.  Discontinuation symptoms in depression and anxiety disorders. , 2007, The international journal of neuropsychopharmacology.

[25]  W. A. Silva,et al.  Culture as a mediator of gene-environment interaction: Cultural consonance, childhood adversity, a 2A serotonin receptor polymorphism, and depression in urban Brazil. , 2016, Social science & medicine.

[26]  D. Nutt,et al.  User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study , 2010 .

[27]  M. Spitzer,et al.  Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: Experimental psychosis as a tool for psychiatric research , 1992, Biological Psychiatry.

[28]  A. Hofmann,et al.  LSD, my problem child , 1980 .

[29]  G. Muehllehner,et al.  Positron emission tomography , 2006, Physics in medicine and biology.

[30]  Stanley Krippner,et al.  LSD: My Problem Child , 1981 .

[31]  D. Nutt,et al.  The paradoxical psychological effects of lysergic acid diethylamide (LSD) , 2016, Psychological Medicine.

[32]  Wim van den Brink,et al.  European rating of drug harms , 2015, Journal of psychopharmacology.

[33]  S. Grof.  Realms of the Human Unconscious: Observations from LSD Research , 1975 .

[34]  E. Malizia,et al.  [THE PSYCHOACTIVE DRUGS. I]. , 1965, La Clinica terapeutica.

[35]  Maarten De Vos,et al.  Detecting Bipolar Depression From Geographic Location Data , 2016, IEEE Transactions on Biomedical Engineering.

[36]  S. Kohli.  The Psychedelic Renaissance: Reassessing the Role of Psychedelic Drugs in 21st Century Psychiatry and Society , 2013 .

[37]  Jacques Binet.  Drugs and Mysticism , 1974 .

[38]  D. Araujo,et al.  Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. , 2015, Revista brasileira de psiquiatria.

[39]  Matthew W. Johnson,et al.  Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness , 2011, Journal of psychopharmacology.

[40]  R. Strassman,et al.  Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study , 2015, Journal of psychopharmacology.

[41]  J. Deakin,et al.  5-HT and mechanisms of defence , 1991, Journal of psychopharmacology.

[42]  D. Nutt,et al.  Experienced Drug Users Assess the Relative Harms and Benefits of Drugs: A Web-Based Survey , 2013, Journal of psychoactive drugs.

[43]  M. Katz,et al.  THE PSYCHOTOMIMETIC DRUGS. AN OVERVIEW. , 1964, JAMA.

[44]  A. Young,et al.  Psychedelics in the treatment of unipolar mood disorders: a systematic review , 2016, Journal of psychopharmacology.

[45]  T. S. Krebs,et al.  Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials , 2012, Journal of psychopharmacology.

[46]  Kevin Murphy,et al.  Neural correlates of the LSD experience revealed by multimodal neuroimaging , 2016, Proceedings of the National Academy of Sciences.

[47]  Martin A. Lee,et al.  Acid dreams: the complete social history of LSD: the CIA, the sixties, and beyond. , 1992 .

[48]  A. House,et al.  Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs , 2004, British Journal of Cancer.

[49]  S. Cohen.  LYSERGIC ACID DIETHYLAMIDE: SIDE EFFECTS AND COMPLICATIONS , 1960, The Journal of nervous and mental disease.

[50]  C. Grob,et al.  Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. , 2011, Archives of general psychiatry.

[51]  A. Mitchell,et al.  Desire for psychological support in cancer patients with depression or distress: validation of a simple help question , 2011, Psycho-oncology.

[52]  W. Richards.  Sacred Knowledge: Psychedelics and Religious Experiences , 2015 .

[53]  R. Griffiths,et al.  Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance , 2006, Psychopharmacology.

[54]  R. Griffiths,et al.  Human hallucinogen research: guidelines for safety , 2008, Journal of psychopharmacology.

[55]  P. Cowen,et al.  ‘It's the way that you look at it’—a cognitive neuropsychological account of SSRI action in depression , 2013, Philosophical Transactions of the Royal Society B: Biological Sciences.

[56]  David J. Nutt,et al.  Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression , 2017 .

[57]  P. Cowen,et al.  Diminished Neural Processing of Aversive and Rewarding Stimuli During Selective Serotonin Reuptake Inhibitor Treatment , 2010, Biological Psychiatry.

[58]  F. Vollenweider,et al.  Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis , 1997, Neuropsychopharmacology.

[59]  D. Murphy,et al.  Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium , 1995, Behavioural Brain Research.

[60]  D. Nutt,et al.  LSD enhances the emotional response to music , 2015, Psychopharmacology.

[61]  G. Murray,et al.  Management of depression for people with cancer (SMaRT oncology 1): a randomised trial , 2008, The Lancet.

[62]  F. Vollenweider,et al.  Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors , 2012, Biological Psychiatry.

[63]  J. Riba,et al.  Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study , 2012, PloS one.

[64]  Matthew W. Johnson,et al.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction , 2014, Journal of psychopharmacology.

[65]  A. Feilding,et al.  LSD enhances suggestibility in healthy volunteers , 2014, Psychopharmacology.

[66]  J. Poirier,et al.  Polymorphism of the 5-HT 2 A receptor gene : Association with stress-related indices in healthy middle-aged adults , 2007 .

[67]  Sandra Maurer,et al.  The Electric Kool Aid Acid Test , 2016 .

[68]  S. Romero,et al.  Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant , 2006, Psychopharmacology.

[69]  K. Audenaert,et al.  Euthanasia requests, procedures and outcomes for 100 Belgian patients suffering from psychiatric disorders: a retrospective, descriptive study , 2015, BMJ Open.

[70]  Matthew W. Johnson,et al.  Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population , 2015, Journal of psychopharmacology.

[71]  J. F. Alonso,et al.  Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans , 2016, European Neuropsychopharmacology.

[72]  Felix Hasler,et al.  Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans , 2007, Psychopharmacology.

[73]  F. Vollenweider,et al.  Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects , 2015, Biological Psychiatry.

[74]  P. Cowen,et al.  What has serotonin to do with depression? , 2015, World psychiatry : official journal of the World Psychiatric Association.

[75]  K. Heekeren,et al.  Psychological Effects of (S)-Ketamine and N,N-Dimethyltryptamine (DMT): A Double-Blind, Cross-Over Study in Healthy Volunteers , 2005, Pharmacopsychiatry.

[76]  M. Mangini,et al.  Treatment of alcoholism using psychedelic drugs: a review of the program of research. , 1998, Journal of psychoactive drugs.

[77]  T. Passie,et al.  Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases , 2014, The Journal of nervous and mental disease.

[78]  D. Sharp,et al.  Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. , 2012, The British journal of psychiatry : the journal of mental science.

[79]  D. Nutt,et al.  Psilocybin with psychological support for treatment-resistant depression: six-month follow-up , 2017, Psychopharmacology.

[80]  J. Belsky.  The Differential Susceptibility Hypothesis: Sensitivity to the Environment for Better and for Worse. , 2016, JAMA pediatrics.

[81]  F. Vollenweider,et al.  The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation , 2017, Current Biology.

[82]  Karl J. Friston,et al.  Broadband Cortical Desynchronization Underlies the Human Psychedelic State , 2013, The Journal of Neuroscience.

[83]  Matthew W. Johnson,et al.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial , 2016, Journal of psychopharmacology.

[84]  Matthew Oram,et al.  Efficacy and Enlightenment: LSD Psychotherapy and the Drug Amendments of 1962 , 2014, Journal of the history of medicine and allied sciences.

[85]  T. Lehtimäki,et al.  Serotonin receptor 2A gene and the influence of childhood maternal nurturance on adulthood depressive symptoms. , 2007, Archives of general psychiatry.

[86]  P. Anderer,et al.  Effects of the South American Psychoactive Beverage Ayahuasca on Regional Brain Electrical Activity in Humans: A Functional Neuroimaging Study Using Low-Resolution Electromagnetic Tomography , 2004, Neuropsychobiology.

[87]  Walter N. Pahnke.  Drugs and Mysticism , 2017 .

[88]  B. Gaynes.  Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities. , 2009, The Journal of clinical psychiatry.

[89]  R. Gregory.  Doors of Perception , 1997, Perception.

[90]  A. Oxman,et al.  Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations , 2006, Health research policy and systems.

[91]  Thomas P. Wolfe,et al.  The Electric Kool-Aid Acid Test , 1968 .

[92]  B. Schmidt,et al.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial , 2016, Journal of psychopharmacology.

[93]  Bryan L Roth,et al.  Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists , 2001, Brain Research Bulletin.